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Background and aims: Incomplete microscopic colitis (MCi) is a subtype of micro-
scopic colitis (MC). Budesonide is recommended as a first‐line treatment for MC.
However, randomised trials on efficacy of treatment in MCi are missing. We
therefore performed a randomised, placebo‐controlled trial to evaluate budesonide
as induction therapy for MCi.
Methods: Patients with active MCi were randomly assigned to either budesonide
9 mg once daily or placebo for 8 weeks in a double‐blind, double‐dummy design. The
primary endpoint was clinical remission, defined as a mean of <3 stools/day and a
mean of <1 watery stool/day in the 7 days before week 8.
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Results: Due to insufficient patient recruitment, the trial was discontinued prema-
turely. The intention‐to‐treat analysis included 44 patients (21 budesonide and 23
placebo). The primary endpoint of clinical remission at week 8 was obtained by
71.4% on budesonide and 43.5% on placebo (p = 0.0582). All clinical secondary
endpoints were in favour of budesonide. Budesonide decreased the number of soft
or watery stools (16.3 vs. 7.7, p = 0.0186) and improved health‐related quality of life
for all four dimensions of the short health scale. Adverse events with a suspected
relation to study drug were reported in one patient in the budesonide group and two
patients in the placebo group. Neither serious nor severe adverse events occurred
during the double‐blind phase.
Conclusions: Budesonide decreased the frequency of soft or watery stools and
improved the patients' quality of life significantly in MCi, but the primary endpoint
was not met due to the low sample size (type 2 error). Budesonide was safe and well
tolerated during the 8‐weeks treatment course.
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INTRODUCTION
The term microscopic colitis (MC) was first used in 1980 to
describe a series of incidental findings in a subset of patients with
chronic watery diarrhoea of unknown origin.1 Since then, MC has
been acknowledged as a separate disease entity and is known to
be a leading cause of chronic non‐bloody diarrhoea, particularly in
elderly women,2–6 with a profound negative impact on the quality
of life.7
Patients with MC present with chronic or recurrent watery
diarrhoea, the colonic mucosa is macroscopically normal or near
normal and histology demonstrates specific histopathological find-
ings,8 usually throughout the colon.9,10
Historically, two main subtypes of MC are distinguished,
collagenous colitis (CC) and lymphocytic colitis (LC). Collagenous
colitis is characterised by a thickened subepithelial collagen band,
that is, >10 μm in well‐oriented biopsies cut perpendicularly to
the surface. Lymphocytic colitis is characterised by an increased
number of intraepithelial lymphocytes (IELs), that is, ≥20 IEL per
100 epithelial cells counted on hematoxylin and eosin (HE)
stained biopsies.8 However, it has become increasingly obvious
that these two entities fail to encompass all histological pre-
sentations of MC.
Thus, in 2011, the term ‘incomplete microscopic colitis’ (MCi)
was proposed by Bjørnbak et al.11 The term was chosen, as in this
entity lymphocytic and collagenous changes are present, yet they
fall short of the criteria defined for either LC or CC.12–14 Patient
characteristics and the subjective response to treatment with
budesonide was, however, similar to those of patients with MC.11
Accordingly, the histological criteria for MCi have been defined as
an increased lymphoplasmacellular infiltrate in the lamina propria,
an abnormally thickened collagenous band (>5 and <10 μm) and/or
abnormal IELs (>5 and <20 per 100 epithelial cells) in HE stained
slides.15
According to an epidemiological study in the United States, of
the 8745 MC patients, LC was diagnosed in 51%, CC in 43% and MCi
in 6%.16 The average age was 63.3 years in LC, 66.4 years in CC and
67.3 years in MCi. There was a striking female predominance in all
the three subtypes (72%–82%).16 To gather similar epidemiological
data, a European registry for all patients diagnosed with MC has been
established in 2015 (PRO‐MC registry; http://www.emcg‐ibd.eu/eu-
ropean‐registry‐promc.html). In the current incidental database of
the PRO‐MC registry, the rate of MCi among all the MC patients is
Key summary
Summarise the established knowledge on this subject
• Incomplete microscopic colitis (MCi) is a subgroup falling
short to fulfilling the classical histological criteria for
microscopic colitis.
• These patients have also chronic watery diarrhoea.
• No treatment has been tested in MCi.
What are the significant and/or new findings of this study?
• Budesonide seems to reduce loose/watery stools.
• Budesonide improves the quality of life in patients with
MCi.
• Budesonide is safe and well tolerated during an 8‐weeks
course.
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14% (data not yet published), thus considerably higher than what has
been reported by Sonnenberg and Genta16 but smaller than the 19%
reported by Bjørnbak et al.11
The discrimination between MCi and MC is subject to inter‐
observer variability, and a revision of the histological criteria of
the MC subtypes has been proposed.17,18 Currently, the diagnosis
of MC and MCi rests on abnormal microscopic findings and the
presence of chronic diarrhoea for at least 1 month.8 In addition to
watery diarrhoea, common symptoms include imperious defecation,
abdominal pain and weight loss.11 The non‐specific clinical presen-
tation and differential diagnoses stress the importance of colonos-
copy and histological assessment for correct diagnosis.8 This is
particularly relevant as there is considerable overlap with the
symptoms of irritable bowel syndrome, which presents with recur-
rent abdominal pain or discomfort as well as changes in stool fre-
quency in the presence of an endoscopically normal intestinal
mucosa.19
In a retrospective cohort study by Bjørnbak et al., clinical char-
acteristics were largely indistinguishable between MC subtypes, and
the highest rates of subjective effectiveness (84%–88%) across all the
three entities were shown for budesonide.11
Most controlled interventional trials on the induction of remis-
sion in patients with MC have been performed with budesonide.8
However, most trials were restricted to either CC or LC. Thus, effi-
cacy data in patients with MCi are largely missing. The objective of
this randomised trial was therefore to fill this data gap and to
demonstrate the superiority of treatment with budesonide (9‐mg
budesonide/day) versus placebo for induction of remission in active
MCi after 8 weeks of treatment.
In most trials, the primary efficacy parameter, clinical remission,
has been determined after 4–8 weeks of double‐blind treatment.
However, several studies indicate that the effect is evident already
after 2 weeks.20,21 To allow for direct comparison with previous
studies, the primary efficacy parameter was therefore determined
after 8 weeks of treatment. In addition, early efficacy was a sec-
ondary efficacy parameter, anticipating that shorter treatment pe-
riods would be potentially feasible in future studies.
METHODS
Study design and conduct
This was a double‐blind, randomised, placebo‐controlled, multi‐
centre, phase 3 study comparing the efficacy and tolerability of
8‐weeks treatment with budesonide (9‐mg gastro‐resistant granules
once daily) versus placebo in patients with MCi. Patients in clinical
remission at the end of the 8‐weeks double‐blind phase entered a 24‐
weeks treatment‐free follow‐up phase. The double‐blind phase took
place between August 2014 and July 2019, and the follow‐up phase
of the last patient was completed in January 2020. The study was
performed at 17 gastroenterology centres in Sweden, Germany,
Austria, Denmark, Hungary, Netherlands, Spain and Lithuania.
The study was registered in the US National Library of Medi-
cine (ClinicalTrials.gov number, NCT02142634) and the EU Clinical
Trials Register (EudraCT number, 2013‐001912‐31). The study
protocol was in accordance with the International Conference on
Harmonization Guideline for Good Clinical Practice and was
approved by the National Ethics Committees of all participating
countries. All patients provided written informed consent. All au-
thors had access to the study data and reviewed and approved the
final manuscript.
Patients
Key inclusion criteria were a history of chronic non‐bloody, watery
diarrhoea for at least 4 weeks and a clinically active disease,
defined as a mean of ≥3 stools/day, thereof a mean of ≥1 watery
stool/day during the week prior to randomisation in patients with
histologically established diagnosis of MCi.22 The key exclusion
criteria were evidence of other significant abnormalities in colo-
noscopy that may have been the cause of diarrhoea, except for
colonic diverticulosis and non‐dysplastic polyps <2 cm; infectious
diarrhoea or history of infectious diarrhoea within the last
3 months prior to inclusion or local intestinal infection; clinical
suspicion of drug‐induced diarrhoea; prior and present MC;
abnormal hepatic function; treatment with immunomodulators
within 3 months prior to baseline; treatment with budesonide or
other steroids or antibiotics within 4 weeks prior to baseline; and
treatment with anti‐diarrheal drugs, cholestyramine, bulking agents,
spasmolytics, bismuth and probiotics within 2 weeks prior to
baseline.
Randomisation and interventions
After a screening phase lasting up to 2 weeks, eligible patients
were randomly assigned to one of the two treatment groups at a
1:1 ratio. For allocation of the patients, a computer‐generated list
of random numbers was prepared using a block size of 4. Group
assignment was blinded for all patients and investigators as well as
all other persons involved in the conduct of the study, by the use
of identical packaging of the different investigational medicinal
products. The consecutively numbered study medication was
dispensed by the investigators according to the randomisation
schedule.
Patients administered either budesonide 9 mg once daily
(1 sachet of Budenofalk® 9‐mg gastro‐resistant granules) or placebo
(1 sachet of placebo Budenofalk® 9‐mg granules), to be taken in the
morning, for 8 weeks. Adherence to the study treatment was moni-
tored by the sachet count at each study visit.
During the entire study period, the use of other anti‐
inflammatory drugs, Boswellia serrata extract, immunosuppressants,
oral or intravenous antibiotics, anti‐diarrheals, spasmolytics, bismuth
and probiotics, was not permitted.
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Sample size
The study protocol pre‐specified a two‐stage group‐sequential
adaptive design with possible sample size adjustment or early stop-
ping of the study for efficacy or futility after the interim analysis.
Assuming the rates of clinical remission of 80% in the budesonide
group and of 50% in the placebo group, the statistical power of the
test procedure was 90% with 35 patients per group in the first stage
and an additional 18 patients per group in the second stage, resulting
in a total sample size of 106 patients (2 � 53 patients) in the
intention‐to‐treat (ITT) analysis.
Evaluation schedule and study endpoints
Post‐baseline study visits took place at weeks 2 (V2), 4 (V3) and 8
(V4) during the double‐blind treatment phase and telephone follow‐
up visits at weeks 20 and 32 post‐randomisation.
The primary endpoint was clinical remission at the week‐8 visit
(applying the last observation carried forward [LOCF] method).
Clinical remission was defined according to the Hjortswang criteria,22
that is, a mean of <3 stools/day and a mean of <1 watery stool/day in
the preceding 7 days.23 Secondary efficacy endpoints included time
to clinical remission, change in the number of watery stools per week,
change in the number of soft or watery stools per week (endpoint
was defined post hoc), change in the number of days without
abdominal pain, change in the quality of life (short health scale [SHS])
and overall safety and tolerability.
Endoscopy and histology
A complete colonoscopy was performed at screening visit (or within
12 weeks before the screening visit) and at the end of the 8‐weeks
double‐blind treatment. At each colonoscopy, two biopsy samples
were obtained from each of the following colon segments: rectum,
sigmoid, descending, transverse, ascending/cecum and terminal
ileum, as an alternative sigmoidoscopy was allowed.
Biopsy specimens were fixed in 4% formalin and embedded in
paraffin. Sections (2–3 μm) were stained with haematoxylin and
eosin. CD3 immunohistochemistry staining was performed if the
number of IELs could not be determined otherwise. Masson‐
Goldner trichrome staining was used to assess the subepithelial
collagen layer. Well‐oriented sections in which at least three
adjacent crypts were cut in their vertical plane were suitable for
evaluation. Sections from each colon section were assessed for the
(i) inflammation of the lamina propria with lymphocytes and
plasma cells (semiquantitative score: 0–3); (ii) inflammation of the
lamina propria with neutrophilic and eosinophilic granulocytes
(semiquantitative score: 0–3); (iii) thickness of the subepithelial
collagen band (μm); (iv) total number of IELs/100 surface epithe-
lium cells; and (v) degeneration of the surface epithelium (present/
absent). All biopsies were analysed in a blinded fashion by a
central pathologist (Daniela Aust, Dresden, Germany). Histological
remission was defined as presence of no/mild lamina propria
inflammation (score < 2 for lymphocytes/plasma cells as well as
for neutrophilic/eosinophilic granulocytes infiltration) and normal
subepithelial collagen band (≤5 μm) and physiological numbers of
IEL (≤5 IEL/100 epithelial cells).
Safety and tolerability
Patients underwent physical examination at the randomisation and
final visit, vital signs and adverse events were recorded at all visits
and general laboratory tests and urinalysis were performed.
Statistical analyses
Efficacy was analysed for the ITT population with a sensitivity anal-
ysis for the per‐protocol (PP) population. Patients with lack of
compliance, intake of forbidden concomitant medication, violation of
eligibility criteria or early discontinuation due to reasons not related
with the study drug were excluded from the PP population. Safety
analyses were performed for the safety population, which included all
patients who took the study drug at least once. As enrolment of
patients was terminated prior to the planned interim analysis due to
an insufficient patient recruitment rate, a two‐stage group‐sequential
adaptive design was no longer appropriate and the test‐statistical
procedure was adjusted (Fisher's exact test). To test the hypothesis
of the primary endpoint, the type I error rate was defined as
α = 0.025 (one‐sided). All other statistical tests were performed two‐
sided with a significance level of α = 0.05 on an exploratory basis. All
statistical analyses were conducted using the SAS statistical package
for Windows (SAS Institute, Cary, NC, USA), version 9.4.
RESULTS
Study population
The sponsor terminated patient recruitment prior to the interim
analysis due to an insufficient patient recruitment rate. A total of 63
patients were screened for enrolment. Of these, 44 patients were
included in the ITT and safety populations (21 budesonide and 23
placebo). Twelve patients discontinued the study prematurely (six
patients in each of both treatment groups). One patient in each of
both treatment groups discontinued the study prematurely due to
adverse events, five patients (2 budesonide and 3 placebo) due to
lack of efficacy and another five patients (3 budesonide and 2 pla-
cebo) for other reasons (Figure S1). The primary analysis was per-
formed for the full analysis set, defined according to the ITT principle.
Five patients (3 of budesonide and 2 of placebo arms) were included
despite being in clinical remission using the Hjortswang criteria and
one patient of the budesonide arm had not histological confirmation
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of MCi. These six patients (besides other patients) were excluded for
the PP analysis which comprised 28 patients.
Baseline demographic and clinical characteristics were similar
in both treatment groups. However, in the placebo group, there
was higher proportions of males, current smokers, of patients
fulfilling the Rome III criteria for diarrhoea‐predominant irritable
bowel syndrome (IBS‐D) and of patients with a longer duration of
diarrhoea (Table 1). Five patients (3 budesonide and 2 placebo)
met one or both Hjortswang criteria for remission at inclusion by
mistake and were thus incorrectly included. Three patients (1
budesonide and 2 placebo) had received budesonide for treatment
of the previous disease. Treatment for the current episode had
been given to six patients, most frequently anti‐diarrheals (n = 3).
As stipulated by the protocol, no patient had been medicated
with budesonide or antibiotics in the 4 weeks prior to baseline.
Clinical efficacy
The primary endpoint of clinical remission at week 8 (LOCF) was met
more frequently in the budesonide group than in the placebo group in
the ITT population (71.4% [15/21] vs. 43.5% [10/23]), however failed
statistical significance (p = 0.0582) (Figure 1a). Similar results were
observed in the PP population (budesonide 75.0% [9/12] vs. placebo
43.8% [7/16], p = 0.1019) (Figure 1b).
The Kaplan–Meier analysis revealed that the median time to
clinical remission was shorter in the budesonide group than the
placebo group (7 vs. 33 days, p = 0.0915) (Figure 2). The mean
number of watery stools during the preceding 7 days decreased
from 15.3 (95% confidence interval (CI) [9.86, 20.81]) at baseline
to 2.8 (95% CI [0.54, 5.08]) at week 8 (LOCF) for the budesonide
group. From baseline to week 8 (LOCF), the mean reduction in the
number of watery stools in the budesonide group was 12.5 (95%
CI [7.22, 17.83]) and in the placebo group 5.4 (95% CI [0.03,
10.69]). The difference between both the treatment groups of the
mean reduction in the number of watery stools was 7.16 (95% CI
[−0.14, 14.46]; p = 0.0542) and evident within 1 week of treat-
ment (Figure 3). The mean reduction in the number of soft or
watery stools in the budesonide group was 16.3 (95% CI [10.60,
21.97]) and in the placebo group 7.7 (95% CI [3.14, 12.31]). The
difference between both the treatment groups in the mean
reduction in the number of soft or watery stools was 8.56 (95% CI
[1.51, 15.61]; p = 0.0186).
The mean number of days without abdominal pain during the
last 7 days before the visit increased by 1.1 (95% CI [0.10, 2.00])
from baseline to week 8 (LOCF) in the budesonide group and
decreased by 0.6 (95% CI [−0.49, 1.76]) in the placebo group. The
difference in the mean number of days without abdominal pain
between both the treatment groups was 1.69 (95% CI [0.24, 3.13];
p = 0.0233).
The mean SHS values decreased (signifying improvement) from
baseline to week 8 (LOCF) in all four health dimensions (symptom
burden, social function, disease‐related worry and general well‐be-
ing). The improvements were greater in the budesonide group versus
the placebo group, and all between‐group differences were statisti-
cally significant: symptom burden 18.95 (95% CI [4.35, 33.54]),
p = 0.0122; social function 19.18 (95% CI [1.68, 36.68]), p = 0.0325;
disease‐related worry 20.73 (95% CI [3.87, 37.59]), p = 0.0172;
general well‐being 28.93 (95% CI [12.50, 45.36]), p = 0.0010
(Figure 4a–d).
TAB L E 1 Baseline demographic and clinical characteristics (ITT population)
Budesonide (n = 21) Placebo (n = 23)
Female gender, number of patients (n) (%) 16 (76.2) 14 (60.9)
Age (years), mean (SD) 52.2 (19.0) 46.5 (15.5)
Body mass index (kg/m2), mean (SD) 25.7 (5.0) 27.2 (5.9)
Smoking habit, n (%)
Current 3 (14.3) 6 (26.1)
Former 7 (33.3) 4 (17.4)
Never 11 (52.4) 13 (56.5)
Caffeine intake, n (%) 18 (85.7) 16 (69.6)
Duration of diarrhoea (years), median (interquartile range) 1.0 (0.4, 3.9) 2.1 (0.7, 4.8)
Acute onset of symptoms, n (%) 15 (71.4) 13 (56.5)
Rome III criteria for IBS‐Da fulfilled, n (%) 13 (61.9) 20 (87.0)
Number of stools/day in the last 7 days, mean (SD) 4.4 (2.1) 4.3 (1.4)
Number of watery stools/day in the last 7 days, mean (SD) 2.2 (1.7) 2.5 (1.7)
Number of soft stools/day in the last 7 days, mean (SD) 1.9 (1.9) 1.4 (1.0)
Abbreviations: ITT, intention‐to‐treat; SD, standard deviation.
aDiarrhoea‐predominant irritable bowel syndrome.
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Histology
Histological examination at baseline confirmed the diagnosis of MCi
in all patients except for one patient in the budesonide group. In this
study, the criterion (iii) – thickened subepithelial collagenous band
(>5 μm and <10 μm) on H&E – was fulfilled in five patients, and the
criterion (iv) – abnormal IELs (>5 and <20 per 100 epithelial cells) on
H&E – was fulfilled in all patients showing an overlap of both criteria
in some patients.
Biopsies were available at week 8 in 27 patients, allowing a
comparison between pre‐ and post‐treatment histology. Histological
remission was achieved in 3/14 and 1/13 patients in the budesonide
and placebo groups, respectively, representing remission rates of
21.4% with budesonide and 7.7% with placebo (p = 0.5956).
Safety
The incidence of adverse events after baseline was slightly higher
in the budesonide (42.9%) versus the placebo group (34.8%)
(Table 2). Adverse events with a suspected relation to study drug
were reported in one patient in the budesonide group (gastro-
esophageal reflux disease) and two patients in the placebo group
(dyspepsia, nausea and rash). Neither serious nor severe (with
respect to intensity) adverse events occurred during the double‐
blind phase. Changes of laboratory parameters attributed to the
study drug or study disease were not clinically relevant in any
treatment group.
DISCUSSION
Despite insufficient patient recruitment and a resulting low
statistical power, results provided supportive evidence that bude-





























































F I GUR E 1 Proportion of patients in clinical remission for
(a) intention‐to‐treat (ITT) population and (b) per‐protocol (PP)
population during the double‐blind phase of the study. Clinical
remission was defined as a mean of <3 stools/day and a mean of <1
watery stools/day in the 7 days prior to week 8 or withdrawal visit
(last observation carried forward method)
*Time from the day of first administration of the IMP to the last day of 7 consecutive days for which the
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F I GUR E 2 Time to clinical remission, defined as the time from the day of first administration of the study drug to the last of ≥7
consecutive days each with on average <3 stools/day thereof <1 watery stool/day (intention‐to‐treat population)
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remission was achieved in 71.4% of patients (43.5% in the placebo
group) after an 8‐weeks course of oral budesonide at a dose of
9 mg/day. Most likely, due to the low sample size, the difference
to placebo was not statistically significant (type 2 error). In
addition, patients reached clinical remission markedly faster with
budesonide (after 1 week, according to the Hjortswang criteria)
than with placebo (after 4–5 weeks). In accordance, a marked
improvement in clinical symptoms, most notably a reduction in the
number of watery or loose stools and days with abdominal pain,
was observed.
The decrease in the combined number of soft or watery stools in
the budesonide group was more than twofold higher than in the
placebo group, implicating a considerable improvement of patient's
quality of life as reflected in the significant improvement in the SHS
as compared to the placebo group.
The low recruitment rate was attributable to several causes,
the most obvious cause being low prevalence and lack of fulfilling
the inclusion criteria (especially amount of watery stools). As
pointed out above, the prevalence of MCi among MC patients
appears to range between 6%16 and 14% (PRO‐MC, unpublished
data). An important obstacle was in many cases that the histo-
logical diagnostic criteria as applied in this trial were not met. The
histologic criteria are based on the assessment of haematoxylin
and eosin stained samples. However, the more extensive use of
CD3 staining highlights the IELs and thus changes the diagnosis
from incomplete MC to LC.18,24 In fact, the incidence of MCi
declined dramatically in parallel with the more extensive use of
CD3 staining in routine practice.25 Langner and colleagues
recommend >10 IEL per 100 epithelial cells as the lower threshold
for the diagnosis of MCi,26 which was recently confirmed by the
recommendations of the United European Gastroenterology and
European Microscopic Colitis Group (EMCG).8 Another obstacle for
correct diagnosis is the inter‐observer variability when discrimi-
nating MCi from CC and LC17,27 and the fact that there is not yet
a consensus on the diagnosis of MCi among pathologists. In sum-
mary, the risk of both over‐ and under‐diagnosis exists and should
be addressed by improved criteria in the future.26,28,29
Efficacy outcomes were largely consistent with the previous re-
sults of various randomised trials as well as observational studies on
the induction of remission in the treatment of the other subtypes of
MC with budesonide.30,31 The EMCG has recently reiterated the
recommendation of budesonide 9 mg/day for 6–8 weeks as first‐line
therapy for active MC, however, without extending the treatment
recommendation specifically to MCi.8 As budesonide is currently the
only drug approved for the treatment of MC, the presented data
suggest that the use of budesonide is also beneficial in the treatment
of active MCi.
The safety results in this study were largely in line with data from
prior trials on treatment of MC with budesonide.30,32,33 No new
safety signal was detected. Budesonide has in general low systemic
effects due to a high first‐pass metabolism in the liver.34–36 As a
result, systemic effects on bone density and adrenal function are less
common with budesonide than with conventional glucocorticoids
such as prednisolone.37,38 Consistently, the recent EMCG guideline
clearly recommends against the use for any corticosteroid other than
budesonide.8
Unfortunately, as only a smaller subset of patients had a
follow‐up endoscopy at the end of treatment, the effect of bude-
sonide on the histological abnormalities cannot be reliably
interpreted.
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F I GUR E 3 Mean number of watery stools/day during the first 28 days (intention‐to‐treat population). A data point reflects the mean
number of watery stools per day during the preceding 7 days
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The main mechanism responsible for budesonide's effect on
diarrhoea appears to be its ability to improve the water‐absorption
capacity of the large bowel.39 Recently, a specific mechanism for
diarrhoea has come into focus which can be called ‘malabsorptive'. In
CC, impaired water resorption may be attributable to down‐
regulation of Aquaporin 8 (AQP8) water channels. In fact, reduced
AQP8 expression may be a common pathomechanism in several
diarrheal disorders as it has also been observed in other inflamma-
tory bowel diseases, infectious colitis and IBS‐D.40–42 Interestingly,
budesonide has been shown to revert the loss of AQP8 expression,
which provides a plausible explanation for its strong anti‐diarrheal
effect.43
Another potentially beneficial effect of budesonide might be the
partial restoration of impaired bile salt absorption. It has been seen
that bile acid malabsorption is common in MC.44,45 Budesonide is
able to induce an increase in ileal bile acid transporter expression in
healthy volunteers46 and to normalise the SeHCAT test results and
reduce bile acid production in patients with CC.45
In this study, 75% of the MCi patients fulfilled the ROME III
criteria for IBS‐D. These results underline the importance to take
biopsies in patients with chronic watery diarrhoea to identify pa-
tients with MC and allow these a rational, evidence‐based treatment.
Limitations
Sample size was lower than intended due to insufficient patient
recruitment. Therefore, statistical power was too low to prove su-
periority of budesonide over placebo for the primary endpoint. In
addition, the small sample size hinders a comprehensive picture on
the range of adverse drug reactions. As pointed out, strict histological



















































































































































F I GUR E 4 Short health scale change from baseline to week 8 (last observation carried forward [LOCF]) (intention‐to‐treat population)
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patients, for example, those suspected to suffer from drug‐induced
disease. However, efficacy was similar to that reported in real‐
world experience.11 Even so, the results cannot be extrapolated to
all individuals with MCi. In this trial, budesonide was administered
using pH‐modified release oral granules (Budenofalk®) which release
the active ingredient only at pH 6.4 or higher,47 that is, specifically in
the target areas terminal ileum and colon. Thus, the current results
may not be applicable to other budesonide formulations with a
different release profile.
CONCLUSION
In summary, 8‐weeks budesonide treatment was effective and safe
for the induction of clinical remission in MCi. More than 71.4% of the
patients achieved clinical remission with a profound improvement
seen already after 1 week of treatment. These results on the efficacy
of budesonide for the treatment of acute MCi are in line with existing
recommendations on other subtypes of MC for induction of
remission.8
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